Drug development for nicotinic acetylcholine receptors (nAChR) is challenged by subtype diversity arising from variations in subunit composition. On-target activity for neuronal heteromeric receptors is typically associated with CNS receptors that contain a4 and other subunits, while off-target activity could be associated with ganglionic-type receptors containing a3b4 binding sites and other subunits, including b4, b2, a5, or a3 as a structural subunit in the pentamer. Additional interest in a3 b4 a5-containing receptors arises from genome-wide association studies linking these genes, and a single nucleotide polymorphism (SNP) in a5 in particular, to lung cancer and heavy smoking. While a3 and b4 readily form receptors in expression system such as the Xenopus oocyte, since a5 is not required for function, simple co-expression approaches may under-represent a5-containing receptors. We used a concatamer of human a3 and b4 subunits to form ligand-binding domains, and show that we can force the insertions of alternative structural subunits into the functional pentamers. These a3b4 variants differ in sensitivity to ACh, nicotine, varenicline, and cytisine. Our data indicated lower efficacy for varenicline and cytisine than expected for b4-containing receptors, based on previous studies of rodent receptors. We confirm that these therapeutically important a4 receptor partial agonists may present different autonomic-based side-effect profiles in humans than will be seen in rodent models, with varenicline being more potent for human than rat receptors and cytisine less potent. Our initial characterizations failed to find functional effects of the a5 SNP. However, our data validate this approach for further investigations.
Introduction
Early single-channel studies of the nicotinic acetylcholine receptors of autonomic neurons revealed a rich diversity of channel subtypes (Papke, 1993) . Although it is now appreciated that, at least in embryonic ganglia, rapidly desensitizing a7-containing nAChRs are of functional importance, blocking a7 receptors in adult animals generally does not impair ganglionic function, and it is likely that the early single-channel studies only detected an array of more slowly desensitizing heteromeric receptor subtypes. We now know, based on recent studies using knockout animals, that ganglionic receptors are primarily assembled as pentameric complexes containing varying arrangements of a3, b2, b4, and a5 subunits (David et al., 2010) .
Although ganglionic blockers were the first drugs used clinically to target neuronal nAChR, most current drug development programs intended to target nAChR in the CNS, either for therapeutics or nicotine dependence, view ganglionic receptors containing a3 in various combinations with b2, b4, and a5 as potential sites for off-target side effects. The human a3-b4-a5 genes are in a cluster at chromosomal location 15q24, and recent genome-wide association studies indicated strong correlations between single nucleotide polymorphisms in the a3-b4-a5 gene cluster and risk for both cancer and nicotine dependence (Chen et al., 2009; Stevens et al., 2008) . Nicotine addiction and dependence has been clearly linked to a4* and a6* receptors (Wu and Lukas, 2011) , and a5 coassembly into a4* receptors also promotes high sensitivity to nicotine, suggesting a link between nicotine use and a4b2a5 receptors (Kuryatov et al., 2011) . However, recent studies have also demonstrated a link between a3b4a5-containing receptors in the medial habenula and nicotine-related behavior, promoting
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receptors with combinations of these subunits as an alternative target for the development of smoking cessation drugs (Fowler et al., 2011; Frahm et al., 2011; Gallego et al., 2011; Salas et al., 2009) .
It has been shown both in vivo (Grady et al., 2009 ) and in heterologous expression systems (Boulter et al., 1990; Gerzanich et al., 1998 ) that a3 will form receptors in various combinations with b2, b4, and a5 subunits. However, a3 and b4 subunits readily form functional receptors without additional subunits, and functional effects of a5 co-expression are much more easily detectable in b2-containing than in b4-containing receptors (Gerzanich et al., 1998) . Therefore, since most effectively targeted drug development relies on the use of receptors with known subunit composition, we adopted a strategy previously shown to be useful for controlling the subunit composition of a4* receptors (Zhou et al., 2003) , by constructing a concatamer of b4 and a3 (b4À6Àa3), suitable for coexpression with monomeric a3, b2, b4, or a5 subunits. The b4À6Àa3 construct will provide ligand-binding domains with a3Àb4 interfaces, so that co-expressed subunit monomers will, with high likelihood, take the fifth position as a structural subunit in the assembled pentamer.
We provide pharmacological validation of hypothesized subunit compositions and characterize the agonist and partial-agonist profiles of the a3b4 receptor subtypes for ACh, nicotine, and the smoking cessation agents, cytisine and varenicline. Cytisine and varenicline have been proposed to have therapeutic utility through potent partial agonist effects on CNS a4-containing receptors.
However, it has been a concern that the reportedly high efficacy of these agents on ganglionic a3-containing receptors might be a source of autonomic side effects. We reevaluate those data and show significant differences from the previously reported data based on the use of rodent receptor subtypes and our current studies based on the use of human receptor clones. Additionally, we used the b4À6Àa3 construct to study the D376N variant of a5, specifically associated with smoking and cancer risks.
Methods and materials

ACh receptor clones
Human nAChR clones were obtained from Dr. Jon Lindstrom (University of Pennsylvania, Philadelphia PA). Alpha3 and b4 were subcloned into the pSGEM vector, obtained from Dr. Michael Hollmann (Ruhr University, Bochum, Germany), which contains Xenopus b-globin untranslated regions to aid Xenopus oocyte expression. Rat nAChR clones were obtained from Dr. Jim Boulter (University of California, Los Angeles).
Concatamer construction
As the C terminus of b4 is of similar length as that of b2, we followed the scheme of Zhou et al. (2003) (Zhou et al., 2003) , and prepared the concatamer with, in sequence: b4 signal, mature b4, 6(AGS) linker, then a3 mature (without signal sequence), all in frame, which should assemble with the a3-b4 binding pocket intact (Zhou et al., 2003) . With this approach, co-injected subunits should co-assemble into the structural, non-ligand-binding-domain position.
Specifically, b4 was mutated silently to introduce a DraIII restriction recognition site just before the stop codon. The site-directed mutagenesis was performed using the QuikChange kit (Agilent Technologies, Santa Clara CA). Long (100 bp) complementary oligos (sense strand: GCTGGAAGGCACAACGTGACGCTGGAAGTGCTGGAAGTGCTGGAAGTGCTGGAA GTGCTGGAAGTGCTGGAAGTGCAGAGGCTGAGCTCGAGACTGAAGC) incorporating the DraIII recognition sequence at the end of b4 before the stop codon, 6(AGS), the first 13 bases of mature a3 coding region including the unique BlpI site, and an XhoI recognition site were annealed following the protocol of Integrated DNA Technologies: Each 4 nmol oligo was dissolved in 40 ml of 100 mM potassium acetate, 30 mM HEPES, pH 7.5. 10 ml of each was combined in a 1.5 ml microcentrifuge tube and placed in a heat block set at 94 ; after 5 min, the heat block was turned off and allowed to slowly return to room temperature, about 2 h. Beta4 and the annealed oligo were digested with DraIII and XhoI. Beta4 was gel-purified, and the oligo was purified with QIAQuick PCR purification kit (Qiagen, Valencia CA) to remove the 12 and 15 bp unwanted pieces while retaining the 73 bp insert. After ligation and plasmid miniprep the construct was confirmed with restriction diagnostics (BlpI). The b4 construct was then subcloned into a3 at the SacII and BlpI sites, thereby creating the b4À6Àa3 concatamer. The final construct was confirmed with automated fluorescent sequencing (University of Florida Biotechnology core facility) as well as by restriction diagnostics.
The a5 single nucleotide polymorphism affecting amino acid translation, a5D376N, was constructed using the QuikChange kit.
Expression in Xenopus laevis oocytes
X. laevis oocytes were surgically removed from frogs (Nasco, Ft. Atkinson WI) and treated with Type I collagenase (Worthington Biochemical Corporation, Freehold NJ) in calcium-free Barth's solution (88 mM NaCl, 1 mM KCl, 2.38 mM NaHCO 3 , 0.82 mM MgS0 4 , 15 mM HEPES (pH 7.6), 12 mg/l tetracycline) in order to remove the follicular layer. Stage-5 oocytes were isolated and injected with 50 nl (3e20 ng) of each cRNA. After linearization and purification of cloned cDNAs, RNA transcripts were prepared in vitro using the appropriate mMessage mMachine kit (Ambion, Austin TX). Recordings were conducted 2e10 days post-injection.
Electrophysiology
Experiments were conducted using OpusXpress6000A (Molecular Devices, Union City, CA). OpusXpress is an integrated system that provides automated impalement and voltage clamp of up to eight oocytes in parallel. Both the voltage and current electrodes were filled with 3 M KCl. The oocytes were clamped at a holding potential of À60 mV. Data were collected at 50 Hz and filtered at 5 Hz. The oocytes were bath-perfused with Ringer's solution (115 mM NaCl, 10 mM HEPES, 2.5 mM KCl, 1.8 mM CaCl 2 ) containing 1 mM atropine to block muscarinic acetylcholine receptors which may be native in the oocytes. Agonist solutions were delivered from 96-deepwell plates using disposable tips. Flow rates were set at 4 ml/ min.
Experimental protocols and data analysis
Responses were calculated as both net charge and peak currents. Each oocyte received initial control applications of 100 mM acetylcholine (ACh), then experimental drug applications, and follow-up control applications of ACh. Responses to experimental drug applications were calculated relative to the preceding ACh control responses in order to normalize the data, compensating for the varying levels of channel expression among the oocytes. A second normalization step was applied to adjust for the empirically determined difference between the 100 mM ACh control responses and the observed ACh maximum for each receptor subtype. Average values and standard errors (SEM) were calculated from the normalized responses of at least four oocytes for each experimental condition. For concentrationeresponse relations, data were plotted using Kaleidagraph 3.0.2 (Abelbeck Software; Reading, PA), and curves were generated from the Hill equation:
I max denotes the maximal response for a particular agonist/subunit combination, and n represents the Hill coefficient. I max , n, and the EC 50 were all unconstrained for the fitting procedures, except in the case of the ACh response curves. Since ACh is our reference full agonist, for the ACh concentrationeresponse curves the data were normalized to the observed ACh maximum, and the I max of the ACh curve fits were constrained to equal one.
Results
Experiments confirming the incorporation of specific structural subunits
When b4À6Àa3 was expressed alone it was capable of forming functional receptors with properties similar to those formed when was b4À6Àa3 co-expressed with b4, suggesting the assembly of a3(2)b4(3) receptors with tethered supernumerary a3 subunits.
That is, the ACh concentrationeresponse curves and the recoveries from TMPH and BTMPS responses were similar (data not shown). In order to obtain better control of structural subunit identity, the RNAs for the monomeric constructs were co-expressed at a fivefold excess to the concatamer. We confirmed pharmacologically that this approach was successful, as shown in Fig. 1 .
When mutations known to increase the reversibility of inhibition by the non-competitive antagonist BTMPS (Francis et al., 1998) were present in the b2 or b4 subunits expressed as monomers, the receptors assembled with the concatamers showed more rapid recovery from inhibition by BTMPS (Fig. 1A) , confirming the functional incorporation of the mutant subunits in the accessory subunit position with the concatamer providing the ligand-binding domains.
We have previously shown that receptors containing a5 subunits have reduced sensitivity to prolonged inhibition by the antagonist TMPH (Papke et al., 2005) , and the co-expression of a5 with the b4À6Àa3 concatamer yielded reduced sensitivity compared to receptors formed with other subunit compositions (Fig. 1B) . We also confirmed that the b4À6Àa3 concatamer could be used to generate functional receptors containing the potentially important a5 single nucleotide polymorphism (SNP) which generates a D376N mutation.
3.2. Pharmacological characterization of a3b4 receptor subtypes
ACh responses
We conducted studies of the ACh concentrationeresponse relationships of the various a3b4 subtypes. The data indicated that substitution of a3, but not a5, for the b4 subunit in the accessory position produced a decrease in ACh potency, while the substitution of a b2 subunit produced receptors with increased ACh sensitivity ( Fig. 2 and Table 1 ). For all of the combinations studied, the kinetics of the ACh-evoked responses were similar with both high and low concentrations of ACh ( Fig. 3 ), so the results based on either peak currents or net charge were equivalent (not shown).
However, as shown in Fig. 3 , the currents of a3 and a5 containing receptors evoked by 1 mM ACh showed decay during the agonist application pulse. This was most likely due to channel block by ACh, consistent with the appearance of rebound current when the ACh began to be washed out of the chamber.
The curves for a3-containing and b2-containing receptors were fit with Hill slopes that were distinctly different than the curves for the b4 and a5 containing receptors. It is difficult to interpret the Hill slopes for macroscopic current responses since multiple factors can (Table 1) were determined by fits of the data to the Hill equation (Methods). A) The b4À6Àa3 concatamer was co-expressed at 1:5 RNA ratio with either wild-type b4 or b2 or with beta subunits containing mutations at the 6 0 and 10 0 sites (Miller, 1989) in the second transmembrane domain (TM2) (b2-2x and b4-2x). These sites have previously been shown to regulate the reversibility of the use-dependent antagonist BTMPS (Francis et al., 1998) . After obtaining two control responses to the application of 100 mM ACh, 3 mM BTMPS was co-applied with 100 mM ACh. While cells expressing wild-type beta subunits showed no significant increase in response between the original co-application response and responses recorded 14e28 min later, cells expressing the beta subunit mutants showed progressive recovery, and responses after 9.2 min (b2-2x) and 18.5 min (b4-2x) were significantly larger than those recorded during the co-application, * indicates p < 0.05, ** indicates p < 0.001. All points represent the average data (AESEM) for at least four cells. B) TMPH is an amphipathic non-competitive antagonist of heteromeric neuronal nAChR, which produces long-lived inhibition of receptors containing only a3 and b4 or a4 and b2 subunits and more readily-reversible inhibition of receptors containing a5 as an accessory subunit. The b4À6Àa3 concatamer was co-expressed at 1:5 RNA ratio with either wild-type b4, b2, or a5 subunits or with the a5D376N variant. After obtaining two control responses to the application of 100 mM ACh, 30 mM TMPH was co-applied with 100 mM ACh. Cells expressing a3 or b4 subunits showed much less recovery after the co-application response than the cells expressing the a5 subunits, where responses after 4.6 min were significantly larger than those recorded during the co-application.
Cells expressing a3 or b4 subunits required 28 min and 9.2 min, respectively, for responses to be significantly larger than those recorded during the co-application, * indicates p < 0.05, ** indicates p < 0.001. At all points after the co-applications the responses of the a5-containing receptors were significantly larger than those of the a3 or b4-containing receptors (p < 0.01). All points represent the average data (AESEM) for at least four cells.
affect the amplitude and kinetics of the responses (Papke, 2009 ).
For example, a steep Hill slope, as seen for the a3(3)b4(2) receptors, could be produced if channel block by agonist became a limiting factor to the ACh-evoked responses, thereby creating a narrow range for effectively increasing ACh-evoked current. In this case of the a3(3)b4(2) receptors the potency for activation is low and does approach the expected potency of ACh for channel block (Lape et al., 2008) . The shallow Hill slope of b2-containing receptors could be due to a mixed population of receptors or possibly alternative subunit interfaces functioning as low potency agonist binding sites.
Nicotine responses
For each of the receptors studied, the waveforms of the nicotineevoked responses were different from the ACh-evoked responses (Fig. 3) , so that concentrationeresponse data based on peak currents and net charge were significantly different (Fig. 4) . Analysis of peak currents suggested that nicotine was a full agonist for a3(2)b4(2)b2 receptors, a 30% partial agonist for a3(2)b4(2)a5 and a3(2)b4(3) receptors, and with intermediate efficacy for a3(3)b4 (2) receptors (Table 2) . At high concentrations of nicotine, evoked responses were protracted for all subunit combinations. For the a3(2)b4(2)b2 receptor net charge data, this effect had the appearance of making nicotine appear more efficacious than ACh, possibly because nicotine was retained at the binding site of these receptors and remained continuously active when the free drug concentrations were being reduced.
It should also be noted that from the appearance of rapid peak currents and subsequent rebounds for several receptors, channel block by nicotine may have also played a role in shaping the unique waveforms of the responses and limiting the apparent efficacy for all subtypes other than the a3(2)b4(2)b2 receptors.
Responses to cytisine and varenicline
Cytisine and varenicline are agents presently in use as smoking cessation aids (Rollema et al., 2010) . Their efficacy for this indication is believe to be related to a potent but weak partial agonism of the a4b2 nAChR subtype(s) (Mihalak et al., 2006; Papke and Heinemann, 1994; Papke et al., 2011 Papke et al., , 2010 which are highly expressed in the CNS. However, these agents have also been reported to be strong activators of ganglionic a3b4* nAChR (Mihalak et al., 2006; Papke and Heinemann, 1994) , a hypothetically off-target effect assumed to be a potential source of autonomic side effects. We evaluated the activity of these agents on the a3b4 receptors formed with different accessory subunits (Fig. 5 ). Contrary to expectations based on prior literature, we found these agents to be only partial agonists of the a3b4 receptor subtypes. Please cite this article in press as: Stokes, C., Papke, R.L., Use of an a3b4 nicotinic acetylcholine receptor subunit concatamer to characterize ganglionic receptor subtypes with specific subunit composition reveals species-specific pharmacologic properties, Neuropharmacology (2012), doi:10.1016/j.neuropharm.2012.04.035
Cytisine was most efficacious but least potent for a3(3)b4 (2) receptors and had an efficacy of no more than 20% that of ACh for the other subtypes tested. The pattern was similar for varenicline except that in all cases it was at least 30-fold more potent than cytisine (Table 3 ). Additionally we noted that that at concentrations higher than 100 mM varenicline, but not cytisine had effects on the response waveforms (not shown) similar to those of nicotine (Fig. 3) , (Shytle et al., 2011) suggesting limiting effects of channel block.
Species-specific features of cytisine and varenicline activation of a3b4 receptors
The initial studies (Mihalak et al., 2006; Papke and Heinemann, 1994) which reported high efficacy of cytisine and varenicline for a3b4 receptors utilized the standard procedure of injecting equal ratios of a3 and b4 RNAs and were conducted using rat cDNA clones. More recently, we reported that for mouse a3b4 receptors, cytisine was a full agonist, while varenicline had an efficacy approximately 50% that of ACh . In order to confirm that the low efficacy we observed for cytisine and varenicline was a characteristic of human a3b4, we conducted direct comparisons between human and rat a3b4 receptors with the standard procedure of monomer co-expression.
ACh responses
As shown in Fig. 6A , the ACh concentrationeresponse curves were nearly identical for rat and human a3b4 receptors, with an ACh potency like that of the a3(2)b4(3) receptors generated with controlled accessory subunit (Table 4) .
Responses to cytisine and varenicline
Consistent with previous data on rat a3b4 (Papke and Heinemann, 1994) we found ( Fig. 6B ) cytisine to be a full agonist for rat a3b4 receptors, although the potency was rather low concentrationeresponse curves. The b4À6Àa3 concatamer was co-expressed at a 1:5 RNA ratio with either a3, b4, b2, or a5. Data were initially normalized to 100 mM ACh control responses obtained immediately prior to the test responses and subsequently adjusted to the empirically determined ACh maximum responses. B) Nicotine netcharge concentrationeresponse curves. The b4À6Àa3 concatamer was co-expressed at a 1:5 RNA ratio with either a3, b4, b2, or a5. Data were initially normalized to 100 mM ACh control responses obtained immediately prior to the test responses and subsequently adjusted to the empirically determined ACh maximum responses. C) The ratio of net charge to peak current (relative to 100 mM ACh controls) for nicotineevoked responses. AeC) Data for progressive increases in nicotine concentration were used from a single experiment only under conditions when ACh controls remained of stable amplitude throughout each experiment. In some cases, nicotine applications prevented the full recovery of ACh controls; in those cases, responses evoked by nicotine relative to ACh were determined in a series of single concentration experiments using new sets of cells for each nicotine concentration. All points represent the average data (AESEM) for at least four cells. however that the expression of monomers did suggest a higher cytisine I max relative to ACh than was seen in the concatamer experiments.
The potency and efficacy of varenicline for human a3b4 in the monomer co-expression experiments (Fig. 6B) were inbetween the values for putative a3(3)b4(2) and a3(2)b4(3) receptors obtained with the concatamer (Table 3) . Although the efficacy of varenicline was similar for rat and human a3b4, the potency of varenicline was approximately 5-fold greater for human than for rat, so that the evoked responses at concentrations from 3 mM to 30 mM varenicline were significantly larger for human than for rat receptors, in striking contrast to the results obtained with cytisine.
3.4. Evaluations of the functional effects of the a5 SNP
Agonist-evoked responses
The a5 SNP D376N was studied along with the wild-type a5 in all of the agonist concentrationeresponse studies (Fig. 7AeC) receptors, most of these drugs also inhibit other nAChR subtypes such as a3b4* receptors (Horenstein et al., 2008) . We evaluated the inhibitory activity of a prototypical agent in this class, GTS-21 (3-(2,4dimethoxybenzylidene)anabaseine) on a3b4 receptors incorporating either wild-type a5 or the a5 SNP as the accessory subunit (Fig. 7D) . The IC 50 for the GTS-21 inhibition of the concatamer coexpressed with wild-type a5 was 9.17 AE 1.08 mM, not significantly different than when co-expressed with a5D376N (8.63 AE 1.41 mM).
Discussion
It has been shown both in vivo and in heterologous expression systems that a3 will form receptors in various combinations with b2, b4, and a5 subunits. Unconstrained expression, when all of these subunits are present, results in a heterogeneous population of receptor subtypes both in neurons and in oocytes. We adopted the strategy of co-expressing a concatamer of b4 and a3 (b4À6Àa3), with monomeric b2, b4, or a5 subunits and were able to confirm that we obtained pharmacologically distinct populations of receptors useful for drug characterization.
For the subtypes specifically associated with the a3Àb4Àa5 gene cluster, our approach to co-expression appeared to be largely successful at generating distinct, potentially homogeneous, populations of receptors. However, it may be noted that the acetylcholine response curve of the putative a3(2)b4(2)b2 receptors (Fig. 2 ) appears as though it may contain two populations of receptors. There appears to be a high sensitivity component, likely to contain b2 subunits, and an incomplete suppression of the a3b4 type receptors that occur when the concatamers were expressed alone. We found that nicotine responses were affected by the identity of the a3b4* structural subunits, as previously reported for a4b2* receptors (Kuryatov et al., 2008) . Receptors containing b2 structural (Table 3) were determined by fits of the data to the Hill equation (Methods).
subunits were most sensitive to low concentrations of nicotine. Our data also indicate that structural subunits will affect the channelblocking activity of nicotine, as well as other non-competitive antagonists.
Our data indicate that the specific a3b4 receptor subtypes will have unique profiles of response to cytisine and related agents that are in development for smoking cessation. Importantly, our data highlighted a disparity between the activity of the agents on human a3b4 receptor subtypes and previous findings based on rodent receptors. It is particularly interesting that the species-specific differences for the two agents tested were in opposite directions and therefore likely to rely on different elements in the receptors. We typically use rodent models for preclinical testing of whole animal drug effects. In the context of our previous studies of mouse nAChR , we noted that cytisine and varenicline have similar activity profiles for rodent and human a4* and a7* type receptors. However, data for human a3b4* receptors were not available at that time. Our current results therefore highlight the potential importance of comprehensive cross-species validation of pharmacology before the translation of preclinical results to human therapeutics. Constipation is a commonly reported side effect of vareniclinebased smoking cessation programs. This side effect might easily be associated with depolarizing block of autonomic ganglia, consistent with the high sensitivity to varenicline we see for human a3b4
receptors. Cytisine (Tabex Ò ) is commonly used as a smoking cessation agent in Europe, and reportedly has only mild sideeffects, which may in part be due to the low sensitivity of human a3b4 receptors to cytisine. Interestingly, a3b4 receptors in the central nervous system (CNS) have also been linked to nicotine's effects on appetite and weight loss (Mineur et al., 2011) , and so differences in the a3b4 activity of specific smoking cessation agents may also affect the process of weight gain that often occurs following successful smoking cessation. Additionally, there have been numerous reports of adverse neuropsychiatric side effects for varenicline, while there have been fewer such reports for cytisine (Moore et al., 2011; Shytle et al., 2011) . The potential importance of a3b4 receptors in the medial habenula and other parts of the brain associated with mood and behavior might suggest that the differences in the neuropsychiatric side effect profiles of varenicline and cytisine could also be related to their differing activity profiles for human a3b4* receptors. The gene for the nAChR a5 subunit was first identified as part of the gene cluster with a3 and b4 in 1990 (Boulter et al., 1990) . The predicted gene product was classified as an alpha subunit based on sequence similarity to other nAChR alpha subunits, most notably the presence of the two vicinal cystines in the structural subdomain of the ligand-binding site currently identified as the C-loop. The a5 gene was subsequently confirmed to be expressed in autonomic ganglia (Wang et al., 2002), hippocampus (Sudweeks and Yakel, 2000) and the cortex (Han et al., 2000) , as well as the particularly nAChR-rich brain structures of the medial habenula and interpeduncular nucleus (Fowler et al., 2011; Grady et al., 2009 ). However, for many years the identification of the protein as a putative alpha subunit was something of a puzzle since it was not functional in heterologous expression systems either alone or in combinations with b2 or b4, subunits known to form functional receptors with neuronal alpha subunits. The a5 subunit was subsequently confirmed to be an obligatory structural subunit that could form functional receptors in combination with a4 and b2, or a3 and b4, and possibly other combinations of subunits which would not require a5 for function (Ramirez-Latorre et al., 1996) (Grinevich et al., 2005) . Although a5 subunits were not required for function, the presence of a5 subunits has significant effects on Fig. 6 . A) ACh concentrationeresponse curves for rat and human a3b4 nAChR formed with the conventional method of co-expressing RNA for the subunit monomers at a 1:1 ratio. B) Cytisine and varenicline concentrationeresponse curves for rat and human a3b4 nAChR formed with the conventional method of co-expressing RNA for the subunit monomers at a 1:1 ratio. All points represent the average data (AESEM) for at least four cells. Statistical analysis based on t-tests between the normalized responses of rat and human receptors indicated significance values of p < 0.01 (*), or p < 0.001 (**). a3b4, 21% a3b4b2, and 24% a3b4a5 nAChRs (David et al., 2010) . Therefore, although a5-containing receptors play a role in autonomic transmission, the knockout of a5 does not produce a serious deficit in autonomic function, as seen with a3 or b4 knockouts (Wang et al., 2002) . Knockout of a5 however, does appear to impact nicotine-mediated behaviors relevant to development of nicotine dependence (Jackson et al., 2011) and adult brain circuitry required for attentional performance (Bailey et al., 2011) . It may be the case that the role of a5, in combination with a3 and b4 in the habenular/ interpeduncular circuit, accounts for the knockout phenotype related to nicotine associated behavior, while the phenotype associated with attentional performance may relate to receptors containing a4 and b2 in combination with a5 in the cortex, hippocampus, and other parts of the brain associated with cognitive function (Bailey et al., 2011) .
The polymorphisms in the a3Àb4Àa5 gene cluster associated with cancer risk and smoking behavior include several variations in untranslated sequence and a single salient mutation in the sequence coding for the a5 subunit protein. This SNP changes an aspartic acid to an asparagine at amino acid 376 (mature protein numbering, or 398 from start codon), a site within the putative amphipathic helix of the intracellular domain. In co-expression studies with a4Àb2 concatamers, Lindstrom and co-workers (Kuryatov et al., 2011) found this mutant in a5 lowered the calcium permeability of the receptors compared to wild-type and may have also affected the receptor's kinetic properties. They studied the effects of the a5 SNP in co-expression with a3 and b4 using the more conventional approach of expressing monomeric subunits at ratios hypothesized to give enriched populations of a5-containing receptors. Using that approach they found no clear effect of the a5 SNP on the calcium permeability of the putative a3b4a5 receptors. Functional effects were also undetected when these subunits were co-expressed in HEK calls (Li et al., 2011) . Consistent with these previous studies, no functional effects of the a5 SNP were detected in the current study on the agonist response profiles of the a3b4a5 receptors. However, as with the introduction of any new experimental tool, our experiments touch upon only a small fraction of the questions that might be addressed.
Conclusion
Receptors containing a3b4 nAChR subunits have long been considered strictly off target for nAChR targeting CNS therapeutics. However, as new roles are being discovered for these receptors in the CNS, in regard to nicotine use and appetite control (Mineur et al., 2011) , it becomes important to characterize the a3b4 receptor subtypes and understand how to target them selectively. Please cite this article in press as: Stokes, C., Papke, R.L., Use of an a3b4 nicotinic acetylcholine receptor subunit concatamer to characterize ganglionic receptor subtypes with specific subunit composition reveals species-specific pharmacologic properties, Neuropharmacology (2012), doi:10.1016/j.neuropharm.2012.04.035 Therefore programs are being developed for high throughput screening of a3b4-containing receptors, and the use of the b4À6Àa3 concatamer will permit detailed follow-up characterizations of potential new drug candidates that may be applied to smoking and other novel CNS indications. Our data additionally highlight the importance of cross characterization of potentially useful therapeutic agents with in vitro tests of both the receptors relevant to animals models and the human receptor subtypes that will ultimately be the molecular targets of therapeutics.
